

Dupilumab shows Good Response in Treating Hand and Facial Eczema in Patients with Moderate to Severe Atopic Dermatitis - Results from the TREATgermany Registry

Susanne Abraham^{1,2}, Katharina Lönnecke², Barbara Kind², Stefan Beissert¹, Andrea Bauer¹, Annice Heratizadeh³, Dora Stölzl⁴, Stephan Weidinger⁴, Thomas Werfel³, Jochen Schmitt² and the TREATgermany Study Group

¹Department of Dermatology, University Allergy Center, Carl Gustav Carus, Faculty of Medicine, Technical University Dresden, Dresden, ²Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Faculty of Medicine, Technical University Dresden, Dresden, ³Department of Dermatology and Allergy, Hannover Medical School, Hannover, ⁴Center for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel



POSTER ID: 64533

Presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025), March 7–11, 2025, Orlando, FL, USA

Introduction

TREATgermany is a prospective multicenter registry for moderate to severe atopic dermatitis (AD) in adult patients, in which currently 2,250 patients are followed up. Till 31 December 2023, 2,012 patients were enrolled in 67 centres, whose data have now been analysed.

Objectives

- To evaluate the response to treatment with dupilumab in patients with involvement of the face or hands with simultaneous severe generalized manifestation of AD.
- Evaluation of isolated moderate to severe hand eczema during treatment with dupilumab.

Methods


TREATgermany collects routine data as a non-interventional, prospective cohort study. The inclusion criteria of the registry are: adults with moderate to severe AD according to the UK Working Party diagnostic criteria, an objective scoring for atopic dermatitis (oSCORAD) >20 despite guideline-compliant topical therapy and/or anti-inflammatory systemic therapy for AD within the past 24 months prior to inclusion in the registry. The first follow-up visit (1. FUV) was scheduled for 3 months: 13 weeks +/- 2 weeks (91 days +/- 14 days) and the second follow-up visit (2. FUV) after 6 months: 26 weeks +/- 4 weeks (182 days +/- 28 days).

Results subgroup 1: Moderate to severe AD and concurrent hand or facial eczema (IGA 3-5)

We analyzed a subgroup 1 (SG 1) of 455 patients with moderate to severe AD (Investigator Global Assessment, IGA 3-5) and concurrent hand or facial eczema (IGA 3-5). Visualization of affected body regions of this SG 1 is shown in Fig.1 and the impairment of quality of life in Tab. 1. 270 of these patients received dupilumab (the other therapies are shown in Fig. 2) and showed an overall good response, see Fig. 3a-c. Quality of life, measured by the Dermatology Life Quality Index (DLQI), improved from 13.9 to 5.5 at the first follow-up visit (1. FUV) after 3 months, see Fig 4. The mean IGA score for hand eczema decreased from 3.3 to 2.1 at 1. FUV, while the mean IGA for facial eczema improved from 3.3 to 2.3 at the same timepoint, see Fig 5. Notably, 9.7% of patients achieved a local IGA score of 0/1 or an improvement of 2 points for hand eczema at 1. FUV, and 14.0% did so for facial eczema.

Fig. 1: Affected body regions of SG 1


Fig. 1: Visualization of body regions (patient-reported) of SG 1 n=455 patients) with moderate to severe AD (Investigator Global Assessment, IGA 3-5) and concurrent hand or facial eczema (IGA 3-5): Shown is the percentage of patients who reported affection of the respective body region by AD in the last 3 days before the baseline visit.



Tab. 1: DLQI, NRS Sleep and Pruritus (SG 1)

Score	n	Mean	Median
DLQI (0-30)	439	13.8	13.0
NRS Impairment of Sleep (0-10)	440	5.6	6.0
NRS Pruritus (0-10)	440	6,9	7.0

Fig. 2: Systemic therapies (SG 1)



Results subgroup 2: Moderate to severe hand eczema (IGA 3-5) and an overall IGA of 0-2

In subgroup 2 (SG 2) with moderate to severe hand eczema (IGA 3-5) and an overall IGA of 0-2 12 patients were treated with dupilumab, see Tab. 2a. 16.7 % achieved a local IGA of 0/1, see Tab. 2b or an improvement by 2 points at 1. FUV, see Tab. 2c.

Tab. 2: IGA hands under therapy with dupilumab (SG 2)

Therapy start visit	IGA Hands			IGA Hands 0/1		IGA Hands -2	
	N	Mean	Median	N	%	N	%
Therapy start visit	12	3.2	3.0	0	0.0	/	/
1. FUV	4	1.5	1.5	2	16.7	2	16.7
2. FUV	3	1.3	1.0	2	16.7	3	25.0

Tab. 2a: Mean IGA Hands Tab. 2b: IGA Hand 0/1 Tab. 2c: IGA Hands -2

Fig. 3: Affected body regions of SG 1 and therapy with dupilumab




Fig. 4: Effectiveness under therapy with dupilumab (SG 1)




Fig. 5: IGA face/hands under therapy with dupilumab (SG 1)





Fig. 6: DLQI, impairment of sleep and pruritus under therapy with dupilumab (SG 2)



Conclusion

Treatment with dupilumab in AD patients resulted in marked improvements in both hand and facial eczema, as well as enhanced quality of life.

Acknowledgements and Disclosures

The authors gratefully acknowledge the substantial contributions made to this work by the participating patients, physicians and clinical staff, the documentation team and the TREATgermany Study Group. TREATgermany is an academic, investigator-initiated clinical disease registry that is financially supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH and Sanofi. Study design, research, analysis, data collection, data interpretation, review, and approval of the poster were performed without financial support. All authors had access to the relevant data and were involved in the preparation, review, and approval of this poster. No honoraria or payments were made for authorship.